Genprex Receives Israel Patent for Reqorsa Gene Therapy Combined with PD-1 Antibodies in Cancer Treatment

Key Takeaways

• Israel Patent Office grants Genprex patent for Reqorsa gene therapy combined with PD-1 antibodies for cancer treatment
• Patent strengthens Genprex’s intellectual property portfolio and expands market protection in key international territory
• Combination therapy approach may enhance cancer treatment effectiveness by targeting multiple pathways simultaneously

---

Genprex, Inc. (NASDAQ: GNPX) announced on April 30, 2026, that The Israel Patent Office has granted the clinical-stage gene therapy company a patent covering the combination use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) with PD-1 antibodies for cancer treatment.

Strengthening International Patent Portfolio

The patent grant represents a significant milestone for the Austin, Texas-based biotechnology company, which focuses on developing innovative therapies for cancer and diabetes patients. This intellectual property protection extends Genprex’s market reach into Israel, a key biotechnology hub in the Middle East.

Reqorsa gene therapy works by delivering therapeutic genes directly to cancer cells, while PD-1 antibodies are immunotherapy drugs that help the immune system recognize and attack cancer cells. The combination approach aims to enhance treatment effectiveness by targeting cancer through multiple mechanisms simultaneously.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Strategic Value

This patent approval strengthens Genprex’s competitive position in the gene therapy market, providing exclusive rights to commercialize this specific combination therapy in Israel. The protection is particularly valuable given the growing interest in combination immunotherapies and gene therapies for cancer treatment.

The Israeli market represents an important strategic territory for biotechnology companies, with the country serving as a gateway to broader Middle Eastern and European markets. Israel’s robust healthcare system and strong pharmaceutical regulatory framework make it an attractive market for innovative cancer therapies.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Clinical Development Progress

Genprex continues advancing Reqorsa through clinical trials as a potential treatment for various cancer types. The combination with PD-1 antibodies represents the company’s strategy to maximize therapeutic potential by leveraging both gene therapy and immunotherapy approaches.

This patent grant follows Genprex’s broader efforts to build a comprehensive intellectual property portfolio protecting its gene therapy innovations across multiple international markets, positioning the company for potential future commercialization and partnership opportunities.

---

Frequently Asked Questions

What does this patent mean for cancer patients?

The patent protects Genprex’s ability to develop and potentially commercialize a combination therapy using Reqorsa gene therapy with PD-1 antibodies in Israel, which could provide patients with a novel treatment approach targeting cancer through multiple mechanisms.

When will Reqorsa combination therapy be available to patients?

Reqorsa is currently in clinical trials, and the timeline for availability depends on successful completion of clinical studies and regulatory approvals. The patent provides protection for future commercialization but doesn’t indicate immediate availability.

How does this combination therapy differ from existing cancer treatments?

This combination uses gene therapy (Reqorsa) to deliver therapeutic genes directly to cancer cells while PD-1 antibodies enhance immune system response, potentially offering a dual-mechanism approach that may be more effective than single-agent therapies.

Related coverage

• Cell and Gene Therapy Approvals in China: Latest Regulatory Updates
• Areas with Risk of Dengue: CDC map, criteria, and global reach
• ASCO26: Revolution's Daraxonrasib Phase III Data Reshapes Pancreatic Cancer Odds